MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

This study is testing whether a blood test (looking at DNA fragments from the tumor in the bloodstream — called ctDNA methylation) can predict how well pancreatic cancer patients respond to surgery or other treatments, and whether it can serve as an early warning sign of recurrence. **You may be eligible if...** - You are 18–80 years old with a suspected pancreatic tumor identified on imaging - You are being considered for surgery or biopsy to confirm the diagnosis - You have adequate blood cell counts, liver, and kidney function - You are willing to provide blood and tissue samples **You may NOT be eligible if...** - You have previously received cancer treatments (chemotherapy, immunotherapy, or radiation) for this cancer - You have another active cancer - You have uncontrolled heart disease, diabetes, or active infection - You have an active autoimmune disease requiring steroids - You are pregnant Talk to your doctor to see if this trial is right for you.